MERSANA THERAPEUTICS
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.
MERSANA THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2005-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.mersana.com
Total Employee:
101+
Status:
Active
Contact:
617-498-0020
Email Addresses:
[email protected]
Total Funding:
480.61 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Protagonist Therapeutics
Protagonist Therapeutics develops orally-stable peptides to treat diseases that are currently addressed by injectable antibodies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Post-IPO Equity - Mersana Therapeutics
Consonance Capital Partners
Consonance Capital Partners investment in Post-IPO Equity - Mersana Therapeutics
Avoro Capital Advisors
Avoro Capital Advisors investment in Post-IPO Equity - Mersana Therapeutics
ArrowMark Partners
ArrowMark Partners investment in Series C - Mersana Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Mersana Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Series C - Mersana Therapeutics
Wellington Management
Wellington Management investment in Series C - Mersana Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series C - Mersana Therapeutics
Takeda
Takeda investment in Series C - Mersana Therapeutics
F-Prime Capital
F-Prime Capital investment in Series B - Mersana Therapeutics
Key Employee Changes
Official Site Inspections
http://www.mersana.com Semrush global rank: 6.43 M Semrush visits lastest month: 1.02 K
- Host name: 204.182.199.35.bc.googleusercontent.com
- IP address: 35.199.182.204
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Mersana Therapeutics"
Home - Mersana Therapeutics
Mersana’s mission is to discover and develop life-changing antibody-drug conjugates for patients fighting cancer.See details»
ESG - Mersana Therapeutics
Executive Team - Mersana Therapeutics
Marty was named President and CEO of Mersana in 2023, bringing to the company extensive drug development experience and demonstrated leadership capabilities across both small and …See details»
Mersana Therapeutics - Crunchbase Company Profile …
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.See details»
Mersana Therapeutics - LinkedIn
Mersana Therapeutics | 11,543 followers on LinkedIn. Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. | At Mersana, we have …See details»
Mersana Therapeutics Provides Business Update and Announces …
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and …See details»
Mersana Therapeutics Announces Second Quarter 2023 Financial …
CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and …See details»
Mersana Therapeutics Provides Business Update and Announces …
CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and …See details»
Mersana Therapeutics Announces Research Collaboration and
Dec 22, 2022 · Immunosynthen, Mersana’s proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both …See details»
About - Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options.See details»
Mersana Therapeutics Provides Business Update and Announces …
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and …See details»
US FDA halts enrollment in Mersana's cancer drug studies, shares …
June 15 (Reuters) - Mersana Therapeutics (MRSN.O) said on Thursday the U.S. Food and Drug Administration (FDA) had paused enrollment in two studies of its ovarian cancer drug after five …See details»
Mersana Therapeutics NasdaqGS:MRSN Stock Report - Simply …
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a …See details»
Mersana Therapeutics Announces Topline Data from UPLIFT …
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and …See details»
About Us - Mersana Therapeutics
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer.See details»
Big Pharma companies invest in ADCs | C&EN Global Enterprise
Jan 2, 2023 · ADCs use their antibody component to guide a drug payload to specific sites in the body. Merck KGaA, in Germany, announced a licensing agreement Dec. 22 with Cambridge, …See details»
Mersana signs deal with Merck KGaA for cancer therapy …
Dec 22 (Reuters) - Mersana Therapeutics Inc (MRSN.O) said on Thursday it had signed a deal for developing cancer drugs with Germany's Merck KGaA (MRCG.DE) that has the potential to …See details»
Merck Announces Collaboration with Mersana Therapeutics to …
Dec 22, 2022 · Mersana has generated preclinical data demonstrating Immunosynthen’s ability to enable highly targeted STING activation within both tumor cells and tumor resident myeloid …See details»
Culture - Mersana Therapeutics
Mersana’s BASE values emphasize the belief that we are at our best as a company when our employees are thriving. We achieve this by fostering a culture that provides opportunities to …See details»
Merck Announces Collaboration With Mersana Therapeutics to …
Dec 22, 2022 · Merck, announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover novel antibody …See details»